Similarly, other class B1 GPCRs, such as the amylin and CRH2 receptors, may provide even further opportunities for developing complementary treatments for metabolic disease, thereby offering the possibility of further expanding the therapeutic potential of the class B1 3GPCRs. This evidence concerns the gene IAPP and metabolic disease.